Mimedx achieved its highest quarterly net sales in company history, reaching $99 million, driven by double-digit growth in both Wound and Surgical product categories. The company also reported a record Adjusted EBITDA of $24 million, reflecting strong operational efficiency and expense discipline. GAAP net income and diluted EPS were $10 million and $0.06, respectively.
Net sales for Q2 2025 reached a record $99 million, a 13% increase year-over-year.
Adjusted EBITDA for the quarter was $24 million, representing 25% of net sales.
Both Wound and Surgical product categories demonstrated strong double-digit growth, contributing to the overall sales increase.
The company raised its 2025 net sales growth expectations to low double-digits for the full year.
Mimedx has raised its 2025 net sales growth expectations to low double-digits and continues to expect adjusted EBITDA margin to be above 20% for the full year and longer-term.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance